Q3FY25 Quarterly Result Announced for Biocon Ltd. - Trendlyne

Jan 31, 2025 · Biotechnology company Biocon announced Q3FY25 results Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore. Reported 7% YoY growth on a like-for-like basis, …

CouponFollow Extension

7%
OFF

Q3FY25 Quarterly Result Announced For Biocon Ltd. - Trendlyne

2 weeks from now

Jan 31, 2025 · Biotechnology company Biocon announced Q3FY25 results Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore. Reported 7% YoY growth on a like-for-like basis, …

trendlyne.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …

2 weeks from now

Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

biocon.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs …

2 weeks from now

Jan 30, 2025 · Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal …

biocon.com

4%
OFF

Biocon Ltd's Q3FY25 Quarter Results - Kotaksecurities.com

2 weeks from now

Jan 31, 2025 · Result Summary. Biocon Ltd reported a 6.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) …

kotaksecurities.com

96%
OFF

Biocon Q3 Results: Profit Plummets 96%; Misses Estimates

2 weeks from now

Jan 30, 2025 · Biocon Ltd.'s Q3FY25 consolidated net profit plummeted 96% to Rs 25 crore, falling short of analysts' estimates. Revenue declined 3.4% to Rs 3,821 crore. Biocon Ltd.'s …

ndtvprofit.com

2%
OFF

F A C T S H E E T - Biocon.com

2 weeks from now

BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT (Rs. Crores) INCOME Generics 686 703 -2% Biosimilars 2,289 2,483 -8% Research services 944 854 11% Inter …

biocon.com

4%
OFF

Here's Why Biocon Share Price Gained 4% Despite Fall In Profits In Q3

2 weeks from now

Jan 31, 2025 · Biocon share price gained 3.82 per cent at Rs 370.80 a piece on the BSE in Friday’s intraday trade after the company’s earnings for the third quarter of financial year 2024 …

business-standard.com

21%
OFF

Biocon Ltd (BOM:532523) (H1 2025) Earnings Call Highlights: …

2 weeks from now

Biocon Ltd (BOM:532523) reports steady biosimilars growth and strategic debt refinancing, despite generics headwinds and net loss. ... 21% decline quarter-over-quarter on a reported …

yahoo.com

44%
OFF

Biocon Quarterly Results, Biocon Financial Statement & Accounts

2 weeks from now

Get Biocon latest Quarterly Results, Financial Statements and Biocon detailed profit and loss accounts. ... Biocon Ltd. Biocon Ltd. | BSE 357.15 1.55 (0.44%) | NSE 357.00 1.30 (0.37%) | …

moneycontrol.com

5%
OFF

Biocon Buys Back An Investor Stake In Biologics Unit, Posts Rs 25 …

2 weeks from now

Jan 30, 2025 · Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, …

indiatimes.com

2%
OFF

Q3FY25 Quarterly Result Announced For Caplin Point ... - Trendlyne

2 weeks from now

1 day ago · Pharmaceuticals company Caplin Point Laboratories announced Q3FY25 results Revenue: Rs 493.0 crore compared to Rs 435.5 crore during Q3FY24, change 13.2%. …

trendlyne.com

35%
OFF

Tata Power Q3 Results 2025 Highlights: Tata Power Q3 PAT Rises

2 weeks from now

4 days ago · Tata Power Q3 Results 2025 Highlights: Tata Power reported a 10.35% rise in net profit for the December quarter, reaching ₹1,187.54 crore, compared to ₹1,076.12 crore last …

livemint.com

35%
OFF

Q3FY25 Quarterly Result Announced For EPACK Durables Ltd.

2 weeks from now

5 days ago · Consumer Electronics company EPACK Durables announced Q3FY25 results Financial Highlights: Revenue Rs 3,768 million YoY: +35% QoQ: Flat. EBITDA Rs 240 million …

trendlyne.com

FAQs about Q3FY25 Quarterly Result Announced for Biocon Ltd. - Trendlyne Coupon?

How did Biocon perform in q3fy25?

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars on a like-for-like basis and an 11 per cent rebound in research services. Biocon’s earnings before interest and taxes (EBIT) amounted to Rs 787 crore, reflecting a 20 per cent margin. ...

How did Pharma perform in q3fy25?

The pharma company’s Q3FY25 consolidated net profit dropped to Rs 25.1 crore, compared to Rs 660 crore in Q3FY24, while revenue for the quarter stood at Rs 3,820 crore, down from Rs 3,954 crore on a year-on-year (Y-o-Y) basis. ...

What are the quarterly results of Biocon Ltd?

The Quarterly Results page of Biocon Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results. Rs 598.90Cr. Rs 80.60Cr. Rs 3.20Cr. Agg. Non-Promoter Share (Lakhs) Agg. Non-Promoter Holding (%) EPS (Rs.) Mutual fund SIP inflow at record high, but why is Nifty down 10% from peak? ...

Why did Biocon grow 10 per cent sequential revenue?

Siddharth Mittal, chief executive officer and managing director, Biocon, noted, “The 10 per cent sequential revenue growth in the generics business was primarily driven by API sales, supported by an improved performance from generic formulations. We expect to see an improved performance in the quarters ahead.” ...

How did Biocon biologics perform in the US biotech market?

The contract development and manufacturing organisation (CDMO), driven by biologics, saw positive momentum, indicating stabilising US biotech market dynamics, though later than expected. Biocon Biologics reported revenue from operations of Rs 2,289 crore, reflecting a 14 per cent yearly increase on a like-for-like basis. ...

Why did the diversified entity report a decline in consolidated profit?

The diversified entity reported a 7.27 per cent decline in consolidated net profit to ₹ 5,013.16 crore for the December quarter due to subdued demand and a sharp escalation in input costs. It had posted a net profit of ₹ 5,406.52 crore in the year-ago period. ...